Publicaciones en las que colabora con Pedro Berraondo López (17)

2024

  1. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2022

  1. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria

    Science Translational Medicine, Vol. 14, Núm. 627

2021

  1. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  2. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1

    British Journal of Cancer, Vol. 124, Núm. 7, pp. 1275-1285

  3. Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors

    Cancers, Vol. 13, Núm. 20

2019

  1. A new immune-nanoplatform for promoting adaptive antitumor immune response

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 13-25

  2. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

    Nature Medicine, Vol. 25, Núm. 3, pp. 470-476

2017

  1. Commentary on Pharmacometrics for Immunotherapy

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 6, Núm. 1, pp. 8-10

2016

  1. Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model

    Oncotarget, Vol. 7, Núm. 47, pp. 76891-76901

2013

  1. Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies

    AAPS Journal, Vol. 15, Núm. 3, pp. 797-807

  2. Modeling tumor response after combined administration of different immune-stimulatory agentss

    Journal of Pharmacology and Experimental Therapeutics, Vol. 346, Núm. 3, pp. 432-442

  3. Target-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice

    AAPS Journal, Vol. 15, Núm. 1, pp. 183-194

2012

  1. Kinetic and dynamic computational model-based characterization of new proteins in mice: Application to interferon alpha linked to apolipoprotein A-I

    PLoS ONE, Vol. 7, Núm. 7

  2. The fusion protein of IFN-α and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism

    Journal of Immunology, Vol. 188, Núm. 8, pp. 3988-3992

2010

  1. Gene therapy: A pharmacokinetic/pharmacodynamic modelling overview

    Pharmaceutical Research, Vol. 27, Núm. 8, pp. 1487-1497

2009

  1. Semi-mechanistic pharmacodynamic modelling of gene expression and silencing processes

    European Journal of Pharmaceutical Sciences, Vol. 37, Núm. 3-4, pp. 418-426

2006

  1. Intrahepatic injection of recombinant adeno-associated virus serotype 2 overcomes gender-related differences in liver transduction

    Human Gene Therapy, Vol. 17, Núm. 6, pp. 601-610